{"protocolSection": {"identificationModule": {"nctId": "NCT01005303", "orgStudyIdInfo": {"id": "RGHT000395"}, "organization": {"fullName": "Belfast Health and Social Care Trust", "class": "OTHER"}, "briefTitle": "Micronutrient Supplementation in Patients With Heart Failure", "officialTitle": "A Trial of Micronutrient Supplementation in Patients With Heart Failure", "acronym": "MINT-HF"}, "statusModule": {"statusVerifiedDate": "2023-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-02"}, "primaryCompletionDateStruct": {"date": "2013-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-10-29", "studyFirstSubmitQcDate": "2009-10-29", "studyFirstPostDateStruct": {"date": "2009-10-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-10-28", "resultsFirstSubmitQcDate": "2023-02-23", "resultsFirstPostDateStruct": {"date": "2023-12-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-02-23", "lastUpdatePostDateStruct": {"date": "2023-12-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Pascal McKeown", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Belfast Health and Social Care Trust"}, "leadSponsor": {"name": "Belfast Health and Social Care Trust", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "There is some evidence to suggest that patients with heart failure may have a reduced dietary intake of vitamins and essential minerals (micronutrients) and that this may worsen the function of the heart. This study is designed to investigate if supplementation with micronutrients (including high-dose vitamin D) will improve the function of the heart in patients with heart failure."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Heart Failure", "Micronutrients", "Vitamin D", "Inflammation", "Oxidative Stress", "Quality of Life", "Physical Functioning"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 79, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}, {"label": "Micronutrient", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Forceval plus 50 micrograms Vitamin D3"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "1 Tablet Daily", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Forceval plus 50 micrograms Vitamin D3", "description": "Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily", "armGroupLabels": ["Micronutrient"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Left Ventricular Ejection Fraction", "timeFrame": "Baseline, and 12 months"}], "secondaryOutcomes": [{"measure": "Quality of Life Questionnaire Score", "description": "Minnesota Living With Heart Failure Questionnaire. The questionnaire is comprised of 21 questions around several physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 (five) scale to indicate the extent to which each itemized adversity of heart failure has prevented the patient from living as they wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses (score range 0-105). Higher scores indicate worse quality of life.", "timeFrame": "Baseline, and 12 months"}, {"measure": "Six Minute Walk Test Distance", "timeFrame": "Baseline, and 12 months"}, {"measure": "Serum N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) Concentration", "timeFrame": "Baseline, and 12 months"}, {"measure": "Serum C-reactive Protein (CRP) Concentration", "timeFrame": "Baseline, and 12 months"}, {"measure": "Serum Tumor Necrosis Factor-alpha (TNF-\u03b1) Concentration", "timeFrame": "Baseline, and 12 months"}, {"measure": "Serum Interleukin-6 (IL-6) Concentration", "timeFrame": "Baseline, and 12 months"}, {"measure": "Serum Interleukin-10 (IL-10) Concentration", "timeFrame": "Baseline, and 12 months"}, {"measure": "Urinary 8-iso-prostaglandin F2 Alpha (8-iso-PGF2\u03b1) Concentration", "timeFrame": "Baseline, and 12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* New York Heart Association Class II and III\n* Already on or tried on best known medical treatment (ACE inhibitor and beta-blocker)\n* Stable for a period of at least 6 weeks\n* Left ventricular ejection fraction less than or equal to 45%\n\nExclusion Criteria:\n\n* History of significant alcohol ingestion (more than 40 units per week)\n* Severe renal dysfunction (GFR less than 30ml/min)\n* Severe hepatic dysfunction (known liver disease or transaminases greater than 3 times the upper limit of normal)\n* Atrial fibrillation (in the absence of a pacemaker)\n* Frequent ventricular ectopics\n* On waiting list for cardiac transplantation\n* Uncontrolled diabetes mellitus\n* Inability to give informed consent\n* Estimated life span less than 12 months\n* Already taking a multivitamin/mineral supplement\n* Already taking a vitamin-D containing fish oil\n* Woman of child-bearing potential\n* History of renal stones, hypercalcaemia, sarcoidosis, haemochromatosis or lactose intolerance", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pascal McKeown, MD", "affiliation": "Belfast Health and Social Care Trust", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Mark Harbinson, MD", "affiliation": "Belfast Health and Socail Care Trust", "role": "STUDY_DIRECTOR"}, {"name": "Michelle McKinley, PhD", "affiliation": "The Queen's Univeristy of Belfast", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Royal Victoria Hospital", "city": "Belfast", "zip": "BT12 6BA", "country": "United Kingdom", "geoPoint": {"lat": 54.59682, "lon": -5.92541}}]}, "referencesModule": {"references": [{"pmid": "24952700", "type": "DERIVED", "citation": "McKeag NA, McKinley MC, Harbinson MT, Noad RL, Dixon LH, McGinty A, Neville CE, Woodside JV, McKeown PP. The effect of multiple micronutrient supplementation on left ventricular ejection fraction in patients with chronic stable heart failure: a randomized, placebo-controlled trial. JACC Heart Fail. 2014 Jun;2(3):308-17. doi: 10.1016/j.jchf.2013.12.008. Erratum In: JACC Heart Fail. 2014 Oct;2(5):549."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "FG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "38"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "comment": "3 patients did not complete the study protocol (2 developed illnesses during the first 3 months of follow-up, requiring withdrawal from the study, and 1 died approximately 6 months into the study).", "numSubjects": "35"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "BG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "74"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.7", "spread": "9.0"}, {"groupId": "BG001", "value": "65.8", "spread": "9.4"}, {"groupId": "BG002", "value": "64.3", "spread": "9.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "14"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "60"}]}]}]}, {"title": "Left Ventricular Ejection Fraction", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of LVEF", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.1", "spread": "9.0"}, {"groupId": "BG001", "value": "38.3", "spread": "11.4"}, {"groupId": "BG002", "value": "41.6", "spread": "10.8"}]}]}]}, {"title": "New York Heart Association Functional Class II", "description": "New York Heart Association Functional Class II = Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). This was assessed via clinical history.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "58"}]}]}]}, {"title": "New York Heart Association Functional Class III", "description": "New York Heart Association Functional Class III = Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.This was assessed via clinical history.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "16"}]}]}]}, {"title": "Aetiology Ischaemic", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "47"}]}]}]}, {"title": "Aetiology Non-Ischaemic", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "27"}]}]}]}, {"title": "Angiotensin Converting Enzyme inhibitor or Angiotensin Receptor Blocker", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "72"}]}]}]}, {"title": "Beta-Blocker", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "70"}]}]}]}, {"title": "Mineralocorticoid Receptor Antagonist", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "37"}]}]}]}, {"title": "Implantable Cardioverter Defibrillator", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "42"}]}]}]}, {"title": "Cardiac Resynchronisation Therapy", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "22"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Left Ventricular Ejection Fraction", "populationDescription": "Result not available for 3 patients: 1 patient was unable to attend for 12 month scan due to personal reasons, 1 patient was unable to attend due to illness and images from 1 patient of inadequate quality for analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of LVEF", "timeFrame": "Baseline, and 12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "OG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "33"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.7", "spread": "8.8"}, {"groupId": "OG001", "value": "38.9", "spread": "11.1"}]}]}, {"title": "12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.9", "spread": "12.0"}, {"groupId": "OG001", "value": "38.6", "spread": "10.9"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Questionnaire Score", "description": "Minnesota Living With Heart Failure Questionnaire. The questionnaire is comprised of 21 questions around several physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 (five) scale to indicate the extent to which each itemized adversity of heart failure has prevented the patient from living as they wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses (score range 0-105). Higher scores indicate worse quality of life.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, and 12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "OG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.7", "spread": "25.2"}, {"groupId": "OG001", "value": "34.0", "spread": "22.6"}]}]}, {"title": "12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "38.2", "spread": "24.1"}, {"groupId": "OG001", "value": "33.1", "spread": "21.6"}]}]}]}, {"type": "SECONDARY", "title": "Six Minute Walk Test Distance", "populationDescription": "Result not available for 6 patients: all were unable to perform six minute walk test due to joint disease / poor mobility.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Metres", "timeFrame": "Baseline, and 12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "OG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "33"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "437.8", "spread": "94.9"}, {"groupId": "OG001", "value": "417.0", "spread": "120.1"}]}]}, {"title": "12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "440.2", "spread": "98.6"}, {"groupId": "OG001", "value": "412.5", "spread": "114.9"}]}]}]}, {"type": "SECONDARY", "title": "Serum N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) Concentration", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/L", "timeFrame": "Baseline, and 12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "OG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "841.6", "spread": "1137.9"}, {"groupId": "OG001", "value": "1293.4", "spread": "2064.1"}]}]}, {"title": "12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "1343.6", "spread": "2983.7"}, {"groupId": "OG001", "value": "1763.6", "spread": "5024.5"}]}]}]}, {"type": "SECONDARY", "title": "Serum C-reactive Protein (CRP) Concentration", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/L", "timeFrame": "Baseline, and 12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "OG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.6", "spread": "8.7"}, {"groupId": "OG001", "value": "6.3", "spread": "15.0"}]}]}, {"title": "12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.3", "spread": "3.8"}, {"groupId": "OG001", "value": "4.6", "spread": "5.4"}]}]}]}, {"type": "SECONDARY", "title": "Serum Tumor Necrosis Factor-alpha (TNF-\u03b1) Concentration", "populationDescription": "Result not available for 3 patients: all due to quality control (intra-assay coefficient of variation \\> 25%).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline, and 12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "OG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.4", "spread": "1.5"}, {"groupId": "OG001", "value": "4.1", "spread": "1.3"}]}]}, {"title": "12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.6", "spread": "1.6"}, {"groupId": "OG001", "value": "4.1", "spread": "1.4"}]}]}]}, {"type": "SECONDARY", "title": "Serum Interleukin-6 (IL-6) Concentration", "populationDescription": "Result not available for 5 patients: all due to quality control (intra-assay coefficient of variation \\> 25%).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline, and 12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "OG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "34"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0", "spread": "6.5"}, {"groupId": "OG001", "value": "7.1", "spread": "12.5"}]}]}, {"title": "12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0", "spread": "6.3"}, {"groupId": "OG001", "value": "4.2", "spread": "3.8"}]}]}]}, {"type": "SECONDARY", "title": "Serum Interleukin-10 (IL-10) Concentration", "populationDescription": "Result not available for 10 patients: all due to due to quality control (intra-assay coefficient of variation \\> 25%).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline, and 12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "OG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "27"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "2.1"}, {"groupId": "OG001", "value": "1.2", "spread": "0.7"}]}]}, {"title": "12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "1.5"}, {"groupId": "OG001", "value": "1.1", "spread": "0.5"}]}]}]}, {"type": "SECONDARY", "title": "Urinary 8-iso-prostaglandin F2 Alpha (8-iso-PGF2\u03b1) Concentration", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mol/mmol creatinine", "timeFrame": "Baseline, and 12 months", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily"}, {"id": "OG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.3", "spread": "5.8"}, {"groupId": "OG001", "value": "12.1", "spread": "7.2"}]}]}, {"title": "12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.7", "spread": "4.6"}, {"groupId": "OG001", "value": "10.5", "spread": "3.8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "12 months", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo: 1 Tablet Daily", "deathsNumAffected": 0, "deathsNumAtRisk": 36, "seriousNumAffected": 18, "seriousNumAtRisk": 36, "otherNumAffected": 0, "otherNumAtRisk": 36}, {"id": "EG001", "title": "Micronutrient", "description": "Forceval plus 50 micrograms Vitamin D3: Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily", "deathsNumAffected": 1, "deathsNumAtRisk": 38, "seriousNumAffected": 10, "seriousNumAtRisk": 38, "otherNumAffected": 0, "otherNumAtRisk": 30}], "seriousEvents": [{"term": "Hospital Admission", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Hospital admission for any reason", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 38}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr Nick McKeag", "organization": "Belfast Health and Social Care Trust", "email": "nick.mckeag@belfasttrust.hscni.net", "phone": "02895048487"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10293", "name": "Inflammation", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T6034", "name": "Quality of Life", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000014807", "term": "Vitamin D"}, {"id": "D000002762", "term": "Cholecalciferol"}], "ancestors": [{"id": "D000014815", "term": "Vitamins"}, {"id": "D000018977", "term": "Micronutrients"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000050071", "term": "Bone Density Conservation Agents"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}], "browseLeaves": [{"id": "M17550", "name": "Vitamin D", "asFound": "Acid", "relevance": "HIGH"}, {"id": "M6003", "name": "Cholecalciferol", "asFound": "Diabetic", "relevance": "HIGH"}, {"id": "M17558", "name": "Vitamins", "relevance": "LOW"}, {"id": "M21009", "name": "Micronutrients", "relevance": "LOW"}, {"id": "M16885", "name": "Trace Elements", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "T479", "name": "Vitamin D3", "asFound": "Diabetic", "relevance": "HIGH"}, {"id": "T442", "name": "Cholecalciferol", "relevance": "LOW"}, {"id": "T440", "name": "Calciferol", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Vi", "name": "Vitamins"}]}}, "hasResults": true}